Drug Discovery

Strategic Industry Analysis: What the Biggest Biopharma Deals of 2025 Reveal About the Future of Drug Innovation

The global biopharmaceutical industry experienced a powerful wave of strategic dealmaking in 2025 as major pharmaceutical companies accelerated…

ByByAnuja Singh Mar 6, 2026

EU Regulators Back CAMCEVI: A Key Step Toward Expanding Prostate Cancer Treatment Options

Foresee Pharmaceuticals has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of…

ByByAnuja Singh Mar 6, 2026

Can aTyr Pharma’s Upcoming FDA Meeting Accelerate the Path to Approval for Efzofitimod?

aTyr Pharma has reported its fourth-quarter and full-year 2025 financial results while outlining a pivotal regulatory milestone ahead:…

ByByAnuja Singh Mar 6, 2026

Did the Zealand Pharma–Roche Obesity Partnership Hit an Early Roadblock?

A closely watched obesity drug collaboration between Zealand Pharma and Roche has encountered an unexpected setback after early…

ByByAnuja Singh Mar 6, 2026
Image Not Found

Can Sanofi’s Twin Lawsuits Against Pfizer and Moderna Reopen the Bill for $140 Billion-Plus in COVID Vaccine Revenue?

Key Highlights Two Companies, One Shared Technology Dispute Sanofi’s complaints, filed as Translate Bio Inc v. Pfizer Inc…

ByByAnuja Singh Jul 16, 2026

Pfizer’s $10 Billion Innovent Alliance: Is China Now the Epicenter of Next-Gen Cancer Drug Discovery?

Key Highlights A Broad Multidrug Alliance Built for Scale The agreement spans up to 12 programs, eight originating…

ByByAnuja Singh Jul 16, 2026
Scroll to Top